Michelucci A, Padeletti L, Fradella G A, Molina Lova R, Monizzi D, Giomi A, Fantini F
Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):254-8.
To evaluate the influence of atropine on atrial refractoriness and its dispersion, we studied ten subjects with sinus bradycardia who were otherwise healthy. Effective and functional refractory periods were measured at three sites of the right atrium (high, middle, and low in the lateral wall), in sinus rhythm and during atrial pacing (120/min), before and after i.v. administration of 0.04 mg/kg of atropine. Both before and after administration, dispersion of atrial refractoriness was determined from the range of refractory periods measured at the three atrial sites as the longest minus the shortest refractory period. Our data indicate that atropine was able to significantly reduce refractoriness and its dispersion. The study protocol allowed us to exclude the possibility that cycle length played a role. The antivagal effect of atropine seemed to explain our findings, even if the possibility that the drug had a direct effect could not be excluded.
为评估阿托品对心房不应期及其离散度的影响,我们对10名窦性心动过缓但其他方面健康的受试者进行了研究。在静脉注射0.04mg/kg阿托品前后,于窦性心律及心房起搏(120次/分钟)时,测量右心房三个部位(侧壁的高、中、低位)的有效不应期和功能不应期。给药前后,均通过测量三个心房部位的不应期范围(最长不应期减去最短不应期)来确定心房不应期离散度。我们的数据表明,阿托品能够显著缩短不应期及其离散度。研究方案使我们能够排除周期长度起作用的可能性。阿托品的抗迷走神经作用似乎可以解释我们的研究结果,尽管不能排除该药物具有直接作用的可能性。